Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Rationale: Giving bortezomib and low doses of chemotherapy and total-body irradiation before
a donor stem cell transplant or peripheral blood stem cell transplant helps stop the growth
of cancer cells. It also stops the patient's immune system from rejecting the donor's stem
cells. The donated stem cells may replace the patient's immune cells and help destroy any
remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a
donor can also make an immune response against the body's normal cells. Giving sirolimus and
tacrolimus before and after transplant may stop this from happening.
Purpose: This phase I/II trial is studying the side effects and best dose of bortezomib
before donor stem cell transplant in treating patients with multiple myeloma.